Johnson & Johnson (JNJ) News Today

Johnson & Johnson (NYSE: JNJ) shares were lower as investors weighed upcoming third-quarter earnings expectations against valuation and longer-term risks. The company’s prior quarter showed 6.6% revenue growth and adjusted EPS above consensus, while full-year 2026 guidance was raised to $11.60–$11.75 per share.

• Positive Sentiment: Johnson & Johnson’s oncology pipeline received favorable attention after Phase 3 data showed the Tecvayli–Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results could support broader use of the therapies, although the combination remains investigational. 2026 Cancer Treatment Advances
• Positive Sentiment: Long-term Phase 3 psoriasis data for oral ICOTYDE reportedly showed maintained skin clearance and consistent safety through Week 112, potentially strengthening JNJ’s immunology pipeline and offering a targeted alternative for difficult-to-treat psoriasis. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Analyst support remains constructive: Guggenheim reaffirmed a Buy rating with a $287 price target, while other recent commentary describes JNJ as an increasingly growth-oriented healthcare company. JNJ Dividend Royalty Status
• Neutral Sentiment: Third-quarter earnings are approaching, with analysts focused on sales, margins, pharmaceutical growth, medical-device performance and management’s outlook for the September 2026 quarter. Forecast revisions or an earnings surprise could be the next major trading catalyst. JNJ Q3 Earnings Preview
• Negative Sentiment: Investors remain cautious because JNJ trades at a premium valuation relative to slower-growing pharmaceutical peers. Commentary also highlights biosimilar competition, a medical-device slowdown and ongoing talc litigation as risks that could limit upside or pressure investor confidence. JNJ Growth Stock Valuation

Overall, the recent decline appears tied more to pre-earnings caution and valuation concerns than to a new fundamental setback. Positive pipeline data and dividend reliability provide support, but investors are likely waiting for confirmation that growth can justify JNJ’s premium multiple.